{"id":57778,"date":"2026-05-26T14:00:00","date_gmt":"2026-05-26T07:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=57778"},"modified":"2026-05-26T14:00:00","modified_gmt":"2026-05-26T07:00:00","slug":"dosisoft-launches-dosisoft-theranostics-a-dedicated-entity-to-accelerate-software-innovation-for-personalized-nuclear-medicine-and-theranostics","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=57778","title":{"rendered":"DOSIsoft Launches DOSIsoft Theranostics, a Dedicated Entity to Accelerate Software Innovation for Personalized Nuclear Medicine and Theranostics"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PARIS<\/span>, May 26, 2026<\/span> \/PRNewswire\/ — Ahead of\u00a0SNMMI 2026, DOSIsoft<\/a>, a leading provider of dosimetry software for radiation oncology and nuclear medicine<\/b>, today announced the launch of DOSIsoft Theranostics<\/b>, a dedicated entity focused on developing theranostics software<\/b> for broader routine clinical adoption<\/b>.<\/p>\n

\u00a0<\/p>\n

As an independent player fully dedicated to theranostics<\/b>, DOSIsoft Theranostics is uniquely positioned to serve the broader clinical and industrial ecosystem as a neutral, trusted software partner<\/b>, with the strategic autonomy to pursue its<\/b> own innovation, partnerships, and long-term investments<\/b>.<\/p>\n

By combining diagnostics with targeted therapies to enable truly personalized treatment, theranostics is entering a new phase of clinical and industrial expansion<\/b>. Building on more than two decades of DOSIsoft expertise<\/b>, DOSIsoft Theranostics will accelerate innovation in software solutions supporting radiopharmaceutical therapies<\/b> and the evolution of nuclear medicine toward more quantitative imaging, AI-driven workflows, and personalized care<\/b>.\u00a0<\/p>\n

Focused on routine clinical use<\/b>, the organization is built for a field where individualized patient therapy monitoring<\/b> increasingly spans multiple imaging modalities, hospital departments, successive treatment cycles, and combined therapeutic approaches<\/b>. Cutting-edge software tools and dedicated scientific expertise<\/b> will also help advance research and clinical innovation.<\/p>\n

At the core of DOSIsoft Theranostics is PLANET\u00ae<\/sup><\/b>, DOSIsoft’s flagship software platform for theranostics. Rooted in DOSIsoft’s heritage in external beam radiation therapy treatment planning<\/b>, PLANET\u00ae<\/sup> has evolved into a comprehensive platform with advanced voxel-based multi-radionuclide dosimetry capabilities<\/b> and full multimodality DICOM interoperability<\/b>. FDA 510(k) cleared and CE marked<\/b>, PLANET\u00ae<\/sup> is deployed in leading hospitals and academic centers worldwide<\/b>, with a vendor-neutral architecture<\/b> that gives clinicians the flexibility to support diverse clinical workflows and therapeutic strategies<\/b>.<\/p>\n

“Creating a dedicated theranostics organization<\/b> reflects DOSIsoft’s long-term commitment<\/b> to this rapidly expanding field.<\/i>\u00a0It<\/i>\u00a0gives DOSIsoft Theranostics the strategic focus and agility<\/b> to accelerate innovation<\/b>, foster new partnerships, and<\/b> expand theranostics applications<\/b> worldwide<\/i>.” said Marc Uszynski, CEO of DOSIsoft.<\/p>\n

DOSIsoft Theranostics will be present at SNMMI 2026<\/a> (#1358)<\/b>.<\/p>\n

About DOSIsoft<\/b><\/p>\n

Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and patient safety. With more than 1,000 installations across 800+ hospital centers in 80 countries, DOSIsoft provides advanced solutions for radiation therapy quality assurance, theranostics, and personalized dosimetry. A spin-off from Gustave Roussy and Institut Curie, DOSIsoft continues to innovate through close collaboration with leading cancer centers worldwide. DOSIsoft is a contributing partner of the European Thera4Care project (Theranostics Ecosystem for Personalized Care).<\/p>\n

CONTACT: chen@dosisoft.fr<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PARIS<\/span>, May 26, 2026<\/span> \/PRNewswire\/ — Ahead of\u00a0SNMMI 2026, DOSIsoft<\/a>, a leading provider of dosimetry software for radiation oncology and nuclear medicine<\/b>, today announced the launch of DOSIsoft Theranostics<\/b>, a dedicated entity focused on developing theranostics software<\/b> for broader routine clinical adoption<\/b>.<\/p>\n

\u00a0<\/p>\n

As an independent player fully dedicated to theranostics<\/b>, DOSIsoft Theranostics is uniquely positioned to serve the broader clinical and industrial ecosystem as a neutral, trusted software partner<\/b>, with the strategic autonomy to pursue its<\/b> own innovation, partnerships, and long-term investments<\/b>.<\/p>\n

By combining diagnostics with targeted therapies to enable truly personalized treatment, theranostics is entering a new phase of clinical and industrial expansion<\/b>. Building on more than two decades of DOSIsoft expertise<\/b>, DOSIsoft Theranostics will accelerate innovation in software solutions supporting radiopharmaceutical therapies<\/b> and the evolution of nuclear medicine toward more quantitative imaging, AI-driven workflows, and personalized care<\/b>.\u00a0<\/p>\n

Focused on routine clinical use<\/b>, the organization is built for a field where individualized patient therapy monitoring<\/b> increasingly spans multiple imaging modalities, hospital departments, successive treatment cycles, and combined therapeutic approaches<\/b>. Cutting-edge software tools and dedicated scientific expertise<\/b> will also help advance research and clinical innovation.<\/p>\n

At the core of DOSIsoft Theranostics is PLANET\u00ae<\/sup><\/b>, DOSIsoft’s flagship software platform for theranostics. Rooted in DOSIsoft’s heritage in external beam radiation therapy treatment planning<\/b>, PLANET\u00ae<\/sup> has evolved into a comprehensive platform with advanced voxel-based multi-radionuclide dosimetry capabilities<\/b> and full multimodality DICOM interoperability<\/b>. FDA 510(k) cleared and CE marked<\/b>, PLANET\u00ae<\/sup> is deployed in leading hospitals and academic centers worldwide<\/b>, with a vendor-neutral architecture<\/b> that gives clinicians the flexibility to support diverse clinical workflows and therapeutic strategies<\/b>.<\/p>\n

“Creating a dedicated theranostics organization<\/b> reflects DOSIsoft’s long-term commitment<\/b> to this rapidly expanding field.<\/i>\u00a0It<\/i>\u00a0gives DOSIsoft Theranostics the strategic focus and agility<\/b> to accelerate innovation<\/b>, foster new partnerships, and<\/b> expand theranostics applications<\/b> worldwide<\/i>.” said Marc Uszynski, CEO of DOSIsoft.<\/p>\n

DOSIsoft Theranostics will be present at SNMMI 2026<\/a> (#1358)<\/b>.<\/p>\n

About DOSIsoft<\/b><\/p>\n

Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and patient safety. With more than 1,000 installations across 800+ hospital centers in 80 countries, DOSIsoft provides advanced solutions for radiation therapy quality assurance, theranostics, and personalized dosimetry. A spin-off from Gustave Roussy and Institut Curie, DOSIsoft continues to innovate through close collaboration with leading cancer centers worldwide. DOSIsoft is a contributing partner of the European Thera4Care project (Theranostics Ecosystem for Personalized Care).<\/p>\n

CONTACT: chen@dosisoft.fr<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-57778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/57778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57778"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/57778\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}